The Quantellect read.As of Nov 19, 2026, 10 active firms cover Summit Therapeutics PLC: 5 rate it Buy or better, 5 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $11.90 to $43.00 (about 3.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $26.79 sits 155% above the current $10.49. The rating mix has stayed broadly stable, with Buy-side ratings easing from 6 to 5 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.19 next quarter toward $-0.79 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 active firms
Neutral
Strong Buy00%
Buy550%
Neutral550%
Sell00%
Strong Sell00%
Based on 10 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$26.79
+155.3% upside
Average target across 10 active firms as of Nov 19, 2026 vs $10.50 current
Highest Target$43.00
Average Target$26.79
Lowest Target$11.90
Detailed analyst forecasts for SMMT
Showing 1–11 of 11 named analysts shown · 10 active firms in the rating projection
As of Nov 19, 2026, 5 of 10 active firms rate SMMT a Buy (5 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
SMMT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.19
Range $-0.23 – $-0.17 · 5 analysts · +10% YoY
Next period, 5 analysts expect Summit Therapeutics PLC to earn $-0.19 a share (range $-0.23 – $-0.17), versus $-0.18 a year earlier. Full-year consensus is $-0.79, growing to $-0.79 the year after.
REVENUE · NEXT QUARTER
$4.8M
Range $0 – $14.3M · 5 analysts
Revenue is expected to reach $4.8M (range $0 – $14.3M). Full-year consensus is $1.9M, rising to $40.1M next year.
Top analysts covering Summit Therapeutics PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SMMT.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #305
Neutral
No targeton SMMT
Overall win rate
33%
+ Follow
#2
Yigal Nochomovitz
Citigroup · Rank #381
Buy
$43.00+309.7% to target
Overall win rate
38%
+ Follow
#3
Daina Graybosch
Leerink Partners · Rank #396
Neutral
$13.00+23.9% to target
Overall win rate
41%
+ Follow
#4
Reni J. Benjamin
JMP Securities · Rank #489
Buy
$40.00+281.1% to target
Overall win rate
29%
+ Follow
#5
Etzer Darout
Barclays
Neutral
$20.00+90.6% to target
Coverage
—
+ Follow
SMMT stock forecast FAQ
What is SMMT's average 12-month price target?+
The 10 active firms with a live target average $26.79 for Summit Therapeutics PLC over the next 12 months, ranging from a $43.00 high to a $11.90 low, as of Nov 19, 2026.
Is SMMT stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 10 active firms as of Nov 19, 2026, 5 rate it Buy or Strong Buy, 5 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for SMMT?+
The Street-high target is $43.00 (Citigroup), and the Street-low is $11.90 (Bernstein). The average of all 10 active-firm targets is $26.79.
How many active Wall Street firms cover SMMT?+
10 active firms have a recognized rating on Summit Therapeutics PLC as of Nov 19, 2026, and 10 active firms carry a live 12-month price target.
Who is the most accurate analyst covering SMMT?+
Among analysts who currently cover SMMT, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #305). Their current call is Neutral.
What is Summit Therapeutics PLC's projected EPS for next quarter?+
The consensus estimate is $-0.19 per share (range $-0.23 – $-0.17) across 5 analysts. Full-year EPS is projected at $-0.79, rising to $-0.79 the following year.
How much revenue is Summit Therapeutics PLC expected to report next quarter?+
Consensus revenue is $4.8M (range $0 – $14.3M). Full-year revenue is projected at $1.9M, growing to $40.1M next year.
Have analysts been upgrading or downgrading SMMT lately?+
As of Nov 19, 2026, 5 of 10 active firms rate SMMT a Buy (5 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SMMT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.